20 February 2025

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

Major new Supply Agreement in the Far East

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce an important new supply agreement in the Far East.

ProBiotix has entered into a material and exclusive long-term partnership agreement with Kemin China Technology Co. Ltd ("KCG"). The deal will allow KCG to sell the Company's proprietary probiotic strain LP_LDL®, as a cardiometabolic health supplement ingredient in China, Hong Kong and Macau, with the opportunity to discuss expansion into other regions, driven by Kemin's global commercial operations. ProBiotix will supply its raw materials in bulk to KCG, whereupon LP_LDL® will be marketed and sold under a co-branding arrangement. With the Far East being a significant market opportunity for ProBiotix, we will continue to retain the rights to sell finished formats under our own brand or as private label in China.

Over 330 million people in China are affected by cardiovascular disease, with two out of five deaths caused by the condition. The Chinese probiotic supplement retail market, was valued in 2024 at $2.3 billion, and is projected to reach $3.6 billion by 2028, a CAGR of 12.8%.

The parent company of KCG is Kemin Industries ("Kemin"), a multinational international ingredients supplier. Founded in 1961, Kemin is headquartered in Iowa in the US, has revenues in excess of $1 billion, and has more than 500 patents and applications. As a global leader, Kemin operates in over 120 countries, and from more than 15 manufacturing facilities worldwide. Its nutrition and health activities are focused on providing functional ingredients sourced from plant-based, natural sources for functional drinks, food and supplements.

Steen Andersen, CEO of ProBiotix, commented: "With the huge prevalence of cardiovascular disease in China, we are delighted to have secured this important, long-term collaboration with KCG, which should provide a significant and sustainable revenue stream to both companies. It provides scope to expand our sales of LP_LDL® in what is a key market for us, through a well-established partner with a strong industry brand. It also complements the recent agreement between ProBiotix and Dancare, who sell and distribute finished products.

As confirmed by our recent trading update, we continue to see ongoing momentum in the business and look forward to updating shareholders on our progress."

Dr Gan Zhilin, President of KCG, commented: "We are glad to partner with ProBiotix in cardiovascular health to address this global health challenge. Relying on ProBiotix's cutting-edge research in the field of probiotic technology and remarkable achievements in improving cardiovascular health, combined with the rich resources of KCG in the Chinese market, we are committed to providing consumers with more efficient and safer cardiovascular health solutions.

This cooperation not only realises the strong combination of technological advantages of both sides, but also the firm practice of our "healthy China" strategy."

For further information, please contact:

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Notes to Editors:

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

The Company has a unique approach; discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.